Form 4: Director Paolo Pucci Receives WST Restricted Stock Units

West Pharmaceutical Services Director Paolo Pucci was granted 791 restricted stock units as part of director compensation.

Summary

• Director Paolo Pucci acquired 791 restricted stock units (RSUs) of West Pharmaceutical Services, Inc. (WST).
• The transaction occurred on May 4, 2026.
• The shares were acquired at a price of $0, representing equity-based compensation.
• Following this transaction, the reporting person's total beneficial ownership is 11,854.297 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None.

Risks

• None.

Future Outlook

The restricted stock units will vest in full on the date of the next annual shareholder meeting and are subject to the company's Deferred Compensation Plan for Outside Directors.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the pharmaceutical packaging and delivery systems sector.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
• The vesting schedule tied to the annual shareholder meeting is a common retention and governance mechanism.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 791 RSUs at the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Equity Grant